Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Momenta, CSL deal

    Momenta granted CSL exclusive, worldwide rights to develop and commercialize preclinical autoimmune candidate M230 and other undisclosed Fc multimer proteins. Momenta expects to begin clinical testing of the selective …

    Published on 1/16/2017
  • PeptiDream, Novartis deal

    PeptiDream received an undisclosed development milestone from Novartis under a 2010 deal, amended in March 2013, to discover macrocyclic peptides against targets from the pharma using PeptiDream's Peptide Discovery …

    Published on 1/16/2017
  • Piqur, Pierre Fabre deal

    Piqur and Pierre Fabre partnered to co-develop Piqurs PQR309 to treat skin cancer. Pierre Fabre will have the option to negotiate exclusive, worldwide rights to the compound in undisclosed skin cancer indications. …

    Published on 1/16/2017
  • Portola, Bristol-Myers, Pfizer deal

    Portola received a $50 million loan from Bristol-Myers and Pfizer to fund development of Portolas AndexXa andexanet alfa as a Factor Xa antidote. The pharmas each contributed $25 million and will each be repaid through …

    Published on 1/16/2017
  • PvP, Takeda deal

    The companies partnered to develop PvP's preclinical celiac disease candidate, KumaMax. PvP will conduct R&D through Phase I trials, and Takeda will provide $35 million. The pharma will also have an exclusive option…

    Published on 1/16/2017
  • Roche, CiVi Biopharma deal

    Newco CiVi Biopharma licensed its lead asset from Roche. The pharma granted CiVi exclusive, worldwide rights to develop and commercialize a candidate against PCSK9 based on Roches Locked Nucleic Acid (LNA) technology …

    Published on 1/16/2017
  • Sanofi, Merck deal

    Merck and Sanofis Sanofi Pasteur S.A. vaccines unit ended their European vaccines JV, Sanofi Pasteur MSD. The 50/50 JV was created in 1994. The partners announced the move last March (see BioCentury, March 14, 2016).…

    Published on 1/16/2017
  • Selten, Vivus deal

    Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary arterial hypertension (PAH) and related vascular diseases. Selten had rights to patents covering …

    Published on 1/16/2017
  • SiteOne Therapeutics, Amgen deal

    The companies partnered to develop SiteOne's Nav1.7 (SCN9A) inhibitors to manage acute and chronic pain. The partners did not respond to inquiries.SiteOne Therapeutics Inc., Bozeman, Mont.Amgen Inc. (NASDAQ:AMGN), …

    Published on 1/16/2017
  • Sun Pharma, Novartis deal

    Sun Pharma acquired Odomzo sonidegib from Novartis for $175 million up front, plus undisclosed milestones. The smoothened (SMO) inhibitor is approved in over 30 countries, including the U.S. and those in the EU, to …

    Published on 1/16/2017
  • Synpromics, General Electric deal

    Synpromics partnered with the GE Healthcare unit of GE to co-develop customized synthetic promoters for GEs biopharmaceutical manufacturing platform. Synpromics will use its PromPT technology to develop a bar-coded …

    Published on 1/16/2017
  • Tot, Lee's deal

    Tot granted the Zhaoke Ophthalmology Pharmaceutical Ltd. subsidiary of Lees exclusive rights to develop and commercialize TAB014 in China, including Hong Kong and Macau. The companies, which said they will share data …

    Published on 1/16/2017
  • Valeant, Sanpower deal

    Valeant is selling cancer company Dendreon Pharmaceuticals Inc. to Sanpower for $819.9 million in cash. Valeant expects the deal to close next quarter. In February 2015, Valeant acquired bankrupt Dendreon's assets, …

    Published on 1/16/2017
  • Vertex, Merck deal

    Vertex granted Merck exclusive, worldwide rights to four cancer programs. Vertex will receive $230 million up front and is eligible for royalties. Merck will be responsible for the programs' development and …

    Published on 1/16/2017
  • Zebra Biologics, AbbVie deal

    Zebra Biologics partnered with AbbVie to discover and develop antibodies to treat inflammatory diseases. Zebra will use its function-based antibody discovery platform to generate antibodies against undisclosed AbbVie …

    Published on 1/16/2017
  • Abzena, Trieza deal

    Abzena granted Trieza exclusive, worldwide rights to an undisclosed antibody sequence for use in combination with Trieza's viral vector technology to develop cancer treatments. The sequence was created using Abzenas …

    Published on 1/9/2017
  • Affimed, MD Anderson deal

    Affimed and MD Anderson partnered to develop and commercialize oncology therapeutics combining MD Anderson's NK cell product with Affimed's TandAb immune cell engager technology. The deal includes Affimed's AFM13, a …

    Published on 1/9/2017
  • Ambrx, MabSpace deal

    Ambrx and MabSpace partnered exclusively to discover and develop oncology antibody drug conjugates (ADCs). The partners will use MabSpace's humanized antibody technology in combination with Ambrx's EuCode conjugation …

    Published on 1/9/2017
  • Amorsa, J&J deal

    The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson partnered with Amorsa to develop therapies for treatment-resistant depression. The partners will use the biotech's ketamine analog technology, and Janssen …

    Published on 1/9/2017
  • Arena, Eisai deal

    Arena amended its licensing agreement with Eisai, granting the Japanese pharma worldwide development and commercialization rights to obesity drug Belviq lorcaserin. Eisai will be responsible for all development and …

    Published on 1/9/2017
  • Axxam, Acousia deal

    Axxam transferred undisclosed assets to Acousia's R&D programs. Acousia is developing small molecules to treat sensorineural hearing loss and to prevent hearing loss in at-risk patients. Last month, Axxam …

    Published on 1/9/2017
  • Bird Rock, J&J deal

    The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson partnered with Bird Rock to develop the biotech's namacizumab. The antibody targets cannabinoid CB1 receptor (CNR1) and is in Phase I testing in healthy …

    Published on 1/9/2017
  • Columbia University, Fortress Biotech deal

    The university granted Fortress newly formed Caelum Biosciences Inc. subsidiary exclusive, worldwide development and commercialization rights to CAEL-101. The chimeric fibril-reactive mAb is in Phase I testing to treat …

    Published on 1/9/2017
  • CymaBay, Kowa deal

    CymaBay granted the Kowa Pharmaceuticals America Inc. subsidiary of Kowa rights in the U.S. to arhalofenate. CymaBay will receive $5 million up front and $10 million in near-term milestones, including the start of a …

    Published on 1/9/2017
  • Eisai, Keio University deal

    Eisai and Keio University partnered to discover and develop therapies to treat and prevent dementia. The partners will establish a jointly staffed lab within the Keio campus, which will use mass spectroscopy, artificial…

    Published on 1/9/2017

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993